Page last updated: 2024-09-05

tbc-11251 and Atrophy

tbc-11251 has been researched along with Atrophy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bellamy, CO; Dhaun, N; Kluth, DC; MacIntyre, IM	1

Other Studies

1 other study(ies) available for tbc-11251 and Atrophy

Article	Year
Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 54, Issue:4 Topics: Amides; Antihypertensive Agents; Atrophy; Biomarkers; Biopsy; Endothelin Receptor Antagonists; Female; Fibrosis; Fumarates; Humans; Hypertension, Renal; Isoxazoles; Kidney; Middle Aged; Proteinuria; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Renin; Scleroderma, Systemic; Thiophenes; Treatment Outcome	2009

Article

Year

Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 54, Issue:4

Topics: Amides; Antihypertensive Agents; Atrophy; Biomarkers; Biopsy; Endothelin Receptor Antagonists; Female; Fibrosis; Fumarates; Humans; Hypertension, Renal; Isoxazoles; Kidney; Middle Aged; Proteinuria; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Renin; Scleroderma, Systemic; Thiophenes; Treatment Outcome

2009